 |
Previous Article | Next Article 
The Journal of Neuroscience, November 15, 2001, 21(22):8765-8771
Exogenous Anandamide Protects Rat Brain against Acute Neuronal
Injury In Vivo
M.
van der Stelt1,
W.
B.
Veldhuis2, 3,
G. W.
van
Haaften1,
F.
Fezza4,
T.
Bisogno4,
P. R.
Bär3,
G. A.
Veldink1,
J. F. G.
Vliegenthart1,
V.
Di
Marzo4, and
K.
Nicolay2
1 Department of Bio-organic Chemistry, Bijvoet Center
for Biomolecular Research, Utrecht University, 3584 CH Utrecht,
The Netherlands, 2 Department of Experimental In Vivo
Nuclear Magnetic Resonance, Image Sciences Institute, Utrecht
University Medical Center, 3584 CJ Utrecht, The Netherlands,
3 Department of Experimental Neurology, Utrecht University
Medical Center, 3584 CX Utrecht, The Netherlands, and
4 Endocannabinoid Research Group, Istituto per la Chimica
di Molecole di Interesse Biologico, Consiglio Nazionale delle Ricerche,
80078 Pozzuoli, Naples, Italy
The endocannabinoid anandamide
[N-arachidonoylethanolamine (AEA)] is thought to
function as an endogenous protective factor of the brain against acute
neuronal damage. However, this has never been tested in an in
vivo model of acute brain injury. Here, we show in a
longitudinal pharmacological magnetic resonance imaging study
that exogenously administered AEA dose-dependently reduced neuronal
damage in neonatal rats injected intracerebrally with the
Na+/K+-ATPase inhibitor ouabain.
At 15 min after injury, AEA (10 mg/kg) administered 30 min before
ouabain injection reduced the volume of cytotoxic edema by 43 ± 15% in a manner insensitive to the cannabinoid CB1
receptor antagonist SR141716A. At 7 d after ouabain treatment,
64 ± 24% less neuronal damage was observed in
AEA-treated (10 mg/kg) rats compared with control animals.
Coadministration of SR141716A prevented the neuroprotective
actions of AEA at this end point. In addition, (1) no increase in AEA
and 2-arachidonoylglycerol levels was detected at 2, 8, or 24 hr after
ouabain injection; (2) application of SR141716A alone did not increase
the lesion volume at days 0 and 7; and (3) the AEA-uptake inhibitor,
VDM11, did not affect the lesion volume. These data indicate that there was no endogenous endocannabinoid tone controlling the acute neuronal damage induced by ouabain. Although our data seem to question a
possible role of the endogenous cannabinoid system in establishing a
brain defense system in our model, AEA may be used as a structural template to develop neuroprotective agents.
Key words:
anandamide; 2-AG; astrogliosis; cannabinoid; excitotoxicity; ischemia; magnetic resonance imaging; neonatal rat; neuronal injury; neuroprotection; ouabain
Copyright © 2001 Society for Neuroscience 0270-6474/01/21228765-07$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
S. DeMorrow, H. Francis, E. Gaudio, J. Venter, A. Franchitto, S. Kopriva, P. Onori, R. Mancinelli, G. Frampton, M. Coufal, et al.
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway
Am J Physiol Gastrointest Liver Physiol,
December 1, 2008;
295(6):
G1150 - G1158.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ludanyi, L. Eross, S. Czirjak, J. Vajda, P. Halasz, M. Watanabe, M. Palkovits, Z. Magloczky, T. F. Freund, and I. Katona
Downregulation of the CB1 Cannabinoid Receptor and Related Molecular Elements of the Endocannabinoid System in Epileptic Human Hippocampus
J. Neurosci.,
March 19, 2008;
28(12):
2976 - 2990.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. DeMorrow, H. Francis, E. Gaudio, Y. Ueno, J. Venter, P. Onori, A. Franchitto, B. Vaculin, S. Vaculin, and G. Alpini
Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation
Am J Physiol Gastrointest Liver Physiol,
February 1, 2008;
294(2):
G506 - G519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev.,
September 1, 2006;
58(3):
389 - 462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Wettschureck, M. van der Stelt, H. Tsubokawa, H. Krestel, A. Moers, S. Petrosino, G. Schutz, V. Di Marzo, and S. Offermanns
Forebrain-Specific Inactivation of Gq/G11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation
Mol. Cell. Biol.,
August 1, 2006;
26(15):
5888 - 5894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. G. Bilsland, J. R. T. Dick, G. Pryce, S. Petrosino, V. Di Marzo, D. Baker, and L. Greensmith
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice
FASEB J,
May 1, 2006;
20(7):
1003 - 1005.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Kim, D. Y. Lee, E. S. Chung, U. T. Oh, S. U. Kim, and B. K. Jin
Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro
J. Neurosci.,
January 19, 2005;
25(3):
662 - 671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Walter, T. Dinh, and N. Stella
ATP Induces a Rapid and Pronounced Increase in 2-Arachidonoylglycerol Production by Astrocytes, a Response Limited by Monoacylglycerol Lipase
J. Neurosci.,
September 15, 2004;
24(37):
8068 - 8074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schenning, C. M. van Tiel, D. van Manen, J. C. Stam, B. M. Gadella, K. W. A. Wirtz, and G. T. Snoek
Phosphatidylinositol transfer protein {alpha} regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor
J. Lipid Res.,
August 1, 2004;
45(8):
1555 - 1564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. El-Remessy, I. E. Khalil, S. Matragoon, G. Abou-Mohamed, N.-J. Tsai, P. Roon, R. B. Caldwell, R. W. Caldwell, K. Green, and G. I. Liou
Neuroprotective Effect of(-){Delta}9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-D-Aspartate-Induced Retinal Neurotoxicity: Involvement of Peroxynitrite
Am. J. Pathol.,
November 1, 2003;
163(5):
1997 - 2008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S. C. Azad, M. G. Cascio, S. O. Gutierrez, M. van der Stelt, et al.
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Science,
October 3, 2003;
302(5642):
84 - 88.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Shrestha, R. A. Dixon, and K. D. Chapman
Molecular Identification of a Functional Homologue of the Mammalian Fatty Acid Amide Hydrolase in Arabidopsis thaliana
J. Biol. Chem.,
September 12, 2003;
278(37):
34990 - 34997.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Leker, N. Gai, R. Mechoulam, and H. Ovadia
Drug-Induced Hypothermia Reduces Ischemic Damage: Effects of the Cannabinoid HU-210
Stroke,
August 1, 2003;
34(8):
2000 - 2006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Molina-Holgado, E. Pinteaux, J. D. Moore, E. Molina-Holgado, C. Guaza, R. M. Gibson, and N. J. Rothwell
Endogenous Interleukin-1 Receptor Antagonist Mediates Anti-Inflammatory and Neuroprotective Actions of Cannabinoids in Neurons and Glia
J. Neurosci.,
July 23, 2003;
23(16):
6470 - 6474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Veldhuis, M. van der Stelt, M. W. Wadman, G. van Zadelhoff, M. Maccarrone, F. Fezza, G. A. Veldink, J. F. G. Vliegenthart, P. R. Bar, K. Nicolay, et al.
Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against In Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases
J. Neurosci.,
May 15, 2003;
23(10):
4127 - 4133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Clement, E. G. Hawkins, A. H. Lichtman, and B. F. Cravatt
Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase
J. Neurosci.,
May 1, 2003;
23(9):
3916 - 3923.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kim, M. Isokawa, C. Ledent, and B. E. Alger
Activation of Muscarinic Acetylcholine Receptors Enhances the Release of Endogenous Cannabinoids in the Hippocampus
J. Neurosci.,
December 1, 2002;
22(23):
10182 - 10191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rueda, B. Navarro, A. Martinez-Serrano, M. Guzman, and I. Galve-Roperh
The Endocannabinoid Anandamide Inhibits Neuronal Progenitor Cell Differentiation through Attenuation of the Rap1/B-Raf/ERK Pathway
J. Biol. Chem.,
November 22, 2002;
277(48):
46645 - 46650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Molina-Holgado, J. M. Vela, A. Arevalo-Martin, G. Almazan, F. Molina-Holgado, J. Borrell, and C. Guaza
Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling
J. Neurosci.,
November 15, 2002;
22(22):
9742 - 9753.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gomez del Pulgar, M. L. de Ceballos, M. Guzman, and G. Velasco
Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway
J. Biol. Chem.,
September 20, 2002;
277(39):
36527 - 36533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Shrestha, M. A. Noordermeer, M. Van der Stelt, G. A. Veldink, and K. D. Chapman
N-Acylethanolamines Are Metabolized by Lipoxygenase and Amidohydrolase in Competing Pathways during Cottonseed Imbibition
Plant Physiology,
September 1, 2002;
130(1):
391 - 401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mechoulam, M. Spatz, and E. Shohami
Endocannabinoids and Neuroprotection
Sci. Signal.,
April 23, 2002;
2002(129):
re5 - re5.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|